Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- Aod9604 is a synthetic HGH fragment that showed modest fat loss in early trials but failed to deliver meaningful weight loss in its pivotal Phase IIb study.
- The peptide is not FDA-approved for any use, was removed from compounding pathways in 2024, and carries immunogenicity concerns flagged by the FDA.
- Aod9604 targets fat metabolism rather than appetite, while GLP-1 medications suppress hunger and have strong Phase III data supporting 12–22% average weight loss.1
- Sourcing risk is high because many research-grade products are impure, so medical supervision and comprehensive lab work are essential before starting any peptide protocol.
- At Mirror Plastic Surgery, Dr. Akash Chandawarkar offers lab-based evaluations and medically supervised peptide therapy; schedule a consultation to explore safe, personalized options.
What Aod9604 Is And How It Was Developed
Aod9604 is a synthetic 16-amino-acid peptide derived from the 176–191 region of human growth hormone (HGH). Metabolic Pharmaceuticals in Australia developed it to stimulate fat breakdown (lipolysis) and inhibit fat storage (lipogenesis) without changing blood sugar or growth hormone levels. It is not FDA-approved for any indication and is not available through FDA-compliant prescription channels.
Researchers engineered Aod9604 to isolate HGH’s fat-metabolism activity while avoiding its growth-promoting and blood-sugar effects. It does not bind growth hormone receptors and does not raise IGF-1 levels. Its development history runs from Metabolic Pharmaceuticals’ obesity program to Lateral Pharma’s later pain research under the name LAT8881. In the United States, Aod9604 is legal to purchase only as a research chemical for laboratory use and is not an approved drug, dietary supplement ingredient, or compound cleared for human use.
Talk with Mirror Plastic Surgery about whether peptide therapy fits your health and weight goals.
How Aod9604 Acts On Fat And Metabolism
Aod9604 appears to act directly on adipose tissue by stimulating beta-3 adrenergic receptors. This activity promotes lipolysis, the breakdown of stored fat into free fatty acids, and may inhibit lipogenesis, the formation of new fat cells. Because it does not bind growth hormone receptors, it does not raise IGF-1 and does not show the glucose dysregulation or insulin resistance associated with excess HGH.
Aod9604 does not suppress appetite. Its proposed effect focuses on fat metabolism, particularly visceral and abdominal fat, rather than central appetite regulation. Even when it reduces a fat depot, that change does not always translate into meaningful scale weight loss. GLP-1 receptor agonists work differently because they suppress hunger and slow gastric emptying.
The FDA’s 2024 Pharmacy Compounding Advisory Committee briefing noted that the molecular targets and mechanisms behind Aod9604’s pharmacologic effects remain uncertain. That uncertainty limits confidence in the theoretical model described above.
Clinical Research On Aod9604 For Weight Loss
An early 12-week multicenter clinical trial with 300 obese participants found that the 1 mg dose group lost an average of 2.6 kg, nearly 2 kg more than placebo.1 The 10 mg dose produced less weight loss, which suggested that effects do not increase with higher doses.
The pivotal Phase IIb trial (METAOD006) told a different story. Investigators enrolled 536 obese adults and treated them for 24 weeks with oral doses of 0.25 mg, 0.5 mg, or 1 mg once daily. Active groups lost about 2.6 kg versus 0.8 kg on placebo, and this difference did not reach statistical significance.1 Development of Aod9604 for obesity ended in 2007.
A 2013 review by Stier, Vos, and Kenley summarized six randomized, double-blind, placebo-controlled human studies involving about 900 participants. The review reported no serious drug-related adverse events, no effect on IGF-1, and no detected anti-Aod9604 antibodies.
The overall efficacy picture is modest and inconsistent. Research on AOD-9604 shows modest fat loss in a 12-week Phase IIa trial (METAOD005), where the 1 mg oral dose group lost about 2.6 kg (roughly 5.7 lbs) versus 0.8 kg for placebo, but the larger 24-week Phase IIb trial failed to show statistically significant weight loss, so results are inconsistent and evidence remains limited. No Phase III trials exist, so Aod9604 remains mechanistically interesting but clinically unproven.
Aod9604 Vs. Glp-1 Medications: A Clinical Comparison
The table below contrasts Aod9604 with FDA-approved GLP-1 agonists across approval status, mechanism, evidence, and regulatory standing so you can see why GLP-1s remain the evidence-backed choice for weight loss.
| Attribute | Aod9604 | Glp-1 Agonists (Semaglutide, Tirzepatide) |
|---|---|---|
| FDA Approval | Not approved for any indication | FDA-approved for weight management |
| Mechanism | Proposed lipolysis stimulation via beta-3 adrenergic receptors, no appetite effect | Appetite suppression, slowed gastric emptying, glucose-dependent insulin release |
| Clinical Evidence | Phase IIb trial failed primary endpoint, no Phase III data, ~900 subjects studied | Robust Phase III programs, 4,500+ (STEP) and 2,500+ (SURMOUNT) participants, 12–22% average weight loss |
| Regulatory Status | Removed from FDA compounding Category 2 (Sept 2024), PCAC voted 12–0 against 503A listing (Dec 2024) | FDA-approved, widely available by prescription |
In the STEP-1 trial, participants taking semaglutide lost an average of about 15% of body weight at 68 weeks.1 In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide lost an average of about 21% of body weight at 72 weeks.1 Glp-1s work through different mechanisms: they suppress appetite and slow gastric emptying. They also carry more significant side effect profiles, particularly gastrointestinal symptoms.
Aod9604’s proposed direct fat-metabolism effect makes it theoretically appealing for people who cannot tolerate GLP-1 medications. Its clinical evidence base is far weaker than GLP-1 data, so it should not replace FDA-approved therapies. Any use belongs within a medically supervised plan.
Aod9604 Dosage And Administration In Practice
The following dosing information comes from limited trial data and clinical experience, not from FDA-approved prescribing information. A physician must individualize dosing and monitor response.
- Typical dose: 250–500 mcg administered subcutaneously once daily, usually in the morning on an empty stomach.
- Cycle length: Many protocols run 12 weeks followed by a 4-week break, although clinical trials have not validated a specific schedule.
- Frequency: Most patients use it once daily, with physicians adjusting frequency based on response and tolerance.
- Onset of effects: Some users notice changes within a few weeks, but 8–12 weeks of consistent use is often needed for visible results.1
The only evidence-based dosing reference comes from oral trials using 0.25–1 mg daily, which does not translate directly to subcutaneous use. A comprehensive lab workup that includes fasting glucose, HbA1c, fasting insulin, IGF-1, lipid panel, and thyroid function tests should occur before starting any peptide protocol.
Side Effects And Safety Of Aod9604
Reported side effects of Aod9604 include injection site irritation, headache, mild nausea, and fatigue. The 2013 Stier, Vos, and Kenley review reported no serious drug-related adverse events across about 900 subjects.
The FDA has raised broader safety concerns. Agency reviewers flagged potential immunogenicity risk, peptide aggregation, peptide-related impurities, challenges in characterizing the active ingredient, and limited long-term safety data. Worst-case immunogenicity outcomes include anaphylaxis and death.
Sourcing creates the most immediate practical risk. Research-grade Aod9604 can have purity levels as low as 60% and is not suitable for human consumption. The owner of Paradigm Peptides received a 70-month federal prison sentence in July 2026 for selling unapproved and adulterated drugs, including peptides marketed for human use with falsified paperwork.
Additional contraindications and restrictions include:
- Pregnancy and breastfeeding: Contraindicated because safety data are insufficient.
- Active or prior cancer: Contraindicated due to theoretical tumorigenesis risk.
- Competitive athletes: Aod9604 appears under Section S2 of WADA’s 2026 Prohibited List and is banned at all times as a non-specified substance.
Who Aod9604 May Suit And Who Should Avoid It
The candidate most likely to consider Aod9604 is an adult with a BMI in the overweight or obese range who has struggled with weight loss despite diet and exercise. This person seeks a metabolic adjunct rather than appetite suppression and understands that Aod9604 does not function as a standalone solution. People who cannot tolerate GLP-1 side effects sometimes explore it as an alternative or adjunct, always under medical supervision.
A comprehensive medical evaluation is essential before starting any peptide protocol. Recommended baseline labs include fasting glucose, HbA1c, fasting insulin, IGF-1, complete metabolic panel, lipid panel, and thyroid panel. Mirror Plastic Surgery follows this approach with every patient, and Dr. Akash Chandawarkar reviews each person’s labs and physiology before designing any protocol.
Arrange a lab-based evaluation with Mirror Plastic Surgery before beginning peptide therapy.
Where To Get Aod9604 Safely: Why Supervision Matters
Buying Aod9604 from unregulated online sources is risky because you cannot verify the product’s purity, dosage, or safety. There is no third-party testing, no meaningful quality control, and no medical oversight to catch problems early. The FDA cannot assure the safety, effectiveness, or quality of any compounded or research-grade product and has issued multiple warning letters to compounding pharmacies and clinics between 2021 and 2025 for unapproved Aod9604 claims and cGMP violations.
Mirror Plastic Surgery offers personalized consultations with Dr. Akash Chandawarkar, a board-certified plastic surgeon trained at Harvard Medical School and Johns Hopkins University, with fellowship training in aesthetic surgery and medical innovation training at Stanford Biodesign. Every protocol begins with comprehensive lab analysis and remains medically supervised throughout treatment. The practice sources peptides from reputable providers with rigorous batch testing, and patients receive concierge-level support with direct access to Dr. Akash.
For a broader overview of peptide options for weight management, the Mirror Plastic Surgery guide to the best peptides for weight loss outlines additional candidates that may fit your individual profile.
Bottom Line: What The Evidence Actually Shows
- Aod9604 shows mechanistic promise but has limited and inconsistent human efficacy data, including a failed pivotal Phase IIb trial.
- The peptide is not FDA-approved, is unavailable through FDA-compliant compounding channels, and carries immunogenicity concerns raised by the FDA.
- Glp-1 medications have far stronger evidence and are FDA-approved for weight loss, although they work through different mechanisms and have their own side effect profiles.
- Aod9604 fits best as a possible adjunct within a comprehensive weight management plan that includes caloric deficit and resistance training, and it should only be used under medical supervision.
Frequently Asked Questions
Is Aod9604 Fda Approved?
Aod9604 is not FDA-approved for weight loss or any other indication. In December 2024, the FDA’s Pharmacy Compounding Advisory Committee voted 12–0 against placing it on the 503A Bulks List, and it was removed from Category 2 in September 2024. No FDA-compliant pathway currently exists for routine compounding of Aod9604 in the United States.
What Are The Side Effects Of Aod9604?
Common side effects reported in clinical trials include injection site reactions, headache, mild nausea, and fatigue. The FDA has flagged potential immunogenicity risk, meaning the peptide could trigger antibody formation, along with concerns about peptide-related impurities. Early trials across about 900 human subjects did not report serious drug-related adverse events, but long-term safety data remain limited. The most severe potential immunogenicity outcome is anaphylaxis.
Can I Take Aod9604 With Ozempic?
Some clinics combine Aod9604 with GLP-1 medications, based on the idea that GLP-1s suppress appetite while Aod9604 targets fat metabolism. This combination should only occur under medical supervision because no clinical data exist on combined use. No studies have evaluated the safety or efficacy of this approach. Mirror Plastic Surgery also offers Glp-3R, a newer-generation peptide similar to GLP-1 that is reported to have fewer gastrointestinal side effects and broader metabolic indications, which may suit some patients better.
How Long Does It Take To See Results With Aod9604?
Some users report changes within a few weeks, but most need 8–12 weeks of consistent use to see noticeable results. In clinical trials, weight loss was modest, with some studies showing roughly 2–5 pounds more than placebo over 12 weeks and inconsistent outcomes across trials.1 Aod9604 does not reduce appetite, so results depend heavily on maintaining a caloric deficit alongside the protocol.1
Is Aod9604 Safe To Buy Online?
Buying Aod9604 from unregulated online sources is unsafe because quality control is poor and purity is uncertain. Research-grade products can be as low as 60% pure, dosing may be inaccurate, and no medical supervision is involved. The FDA cannot assure the safety or quality of products obtained outside legitimate medical channels. Federal prosecutors have pursued online peptide vendors, and at least one seller received nearly six years in prison for selling unapproved and adulterated drugs.
Conclusion: How To Decide Whether Aod9604 Fits Your Plan
Aod9604 is a scientifically interesting compound with a failed pivotal trial, a closed regulatory pathway, and meaningful sourcing risks. Its evidence base does not support use as a standalone weight-loss therapy, and it does not replace FDA-approved options with robust Phase III data. At most, it may serve as a modest metabolic adjunct within a comprehensive, physician-supervised plan.
The peptide therapy landscape extends well beyond Aod9604. Options range from Glp-3R for weight and metabolic health to Sermorelin and Ipamorelin for lean body composition. The right protocol depends on your labs, physiology, and goals rather than a one-size-fits-all approach. Mirror Plastic Surgery offers advanced peptide therapies for concerns that include inflammation, autoimmune conditions, weight management, and anti-aging. Schedule a personalized consultation to explore how a tailored, lab-based peptide plan can help you reach your goals safely and effectively.
This article is for informational purposes only and does not constitute medical advice. Results vary from person to person. Always consult a qualified healthcare provider before starting any peptide therapy or weight loss program. Aod9604 is not FDA-approved for any indication, and its safety and efficacy have not been established by the FDA.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
